Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Two major Brazilian trials tested aggressive blood pressure targets in different high-risk groups — with strikingly different results. In stroke/TIA patients, targeting systolic BP below 120 mm Hg significantly cut major cardiovascular events. But in type 2 diabetes patients, the same aggressive target showed no significant benefit over standard care, though a pooled meta-analysis hints at a modest protective effect.
Two large randomized trials — OPTIMAL-STROKE and OPTIMAL-DIABETES — presented at the American Heart Association Scientific Sessions and published simultaneously in the New England Journal of Medicine tested whether targeting a systolic blood pressure (BP) below 120 mm Hg beats the standard target of below 140 mm Hg in reducing major cardiovascular (CV) events.
OPTIMAL-STROKE delivered a clear win: among 4,368 patients with prior ischemic stroke or TIA, intensive BP lowering reduced the composite of CV death, nonfatal MI, nonfatal stroke, or hospitalization for unstable angina or heart failure (10.9% vs. 13.5%, HR 0.79). This is the first adequately powered trial to show this benefit in a post-stroke population — a group historically excluded from trials like SPRINT. OPTIMAL-DIABETES, however, was neutral: among 9,476 patients with type 2 diabetes and high CV risk, the same intensive strategy showed no significant difference in outcomes (6% vs. 6.7%, HR 0.90, P=0.20). A pre-specified meta-analysis combining OPTIMAL-DIABETES with BPROAD and ACCORD BP did suggest a 16% relative reduction in major CV events with intensive BP lowering.
By the Numbers:
Why it matters: These trials reshape how clinicians should think about BP targets across different patient populations. For stroke/TIA survivors, aggressive BP control is now backed by strong evidence. For diabetes patients, the picture remains nuanced — the individual trial is neutral, but the totality of evidence leans toward benefit, and experts suggest longer follow-up or subgroup analyses may yet reveal a clearer signal.